BioCentury
ARTICLE | Finance

Celgene sticks with the combo

Celgene a contrarian on chairman-CEO

February 2, 2018 10:07 PM UTC

While the market showed relative indifference to the appointment of CEO Mark Alles to the additional role of chairman of Celgene Corp. (NASDAQ:CELG), it goes against the trend among the big biotechs.

On Jan. 29 Celgene announced that Alles will become chairman effective Feb. 5 following the retirement of former CEO and current Executive Chairman Robert Hugin...